Prognostic factors in patients with soft palate squamous cell carcinoma.
Adult
Age Factors
Aged
Carcinoma, Squamous Cell
/ mortality
Chemoradiotherapy
/ methods
Cohort Studies
Combined Modality Therapy
Databases, Factual
Disease-Free Survival
Dose Fractionation, Radiation
Female
Humans
Male
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness
/ pathology
Neoplasm Recurrence, Local
/ mortality
Neoplasm Staging
Palatal Neoplasms
/ mortality
Palate, Soft
/ pathology
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Sex Factors
Survival Analysis
Treatment Outcome
biomarkers
head and neck cancer
prognostic factor
squamous cell carcinoma
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
11
2017
revised:
02
10
2018
accepted:
05
12
2018
pubmed:
13
1
2019
medline:
24
11
2020
entrez:
13
1
2019
Statut:
ppublish
Résumé
To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC). Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined. We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05). In patients with soft palate SCC, inflammation biomarkers were associated with OS.
Sections du résumé
BACKGROUND
To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC).
METHODS
Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined.
RESULTS
We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05).
CONCLUSION
In patients with soft palate SCC, inflammation biomarkers were associated with OS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1441-1449Informations de copyright
© 2019 Wiley Periodicals, Inc.